Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220564 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
A Phase 1 study of Haemophilia A, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 18
- Study locations
NCT07220564: Recruiting Phase 1 study of Haemophilia A, sponsored by Novo Nordisk A/S.
NCT07220564 is a Phase 1 study of Haemophilia A that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 20 participants, below the 223-participant average among 8 other Haemophilia A trials with a reported enrollment target (91% lower). The trial reports 18 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220564, a Phase 1 study of Haemophilia A, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.
Primary Outcome
Measured as count of events.
Conditions Studied
Interventions
- DRUG NNC0442-0344 A
Study Locations (18)
Other
- Universitätsklinik für Innere Medizin V - Innsbruck
- AKH - Klin. Abt. f. Haematologie u. Haemostaseologie - Vienna
- Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain - Berlin
- Medizinische Hochschule Hannover - Hämatologie, Hämostaseologie, Onkologie - Hanover
- AOU Careggi Firenze - Florence
- Azienda Ospedaliera Universitaria Federico II di Napoli - Naples
- Uniwersytecki Szpital Kliniczny w Bialymstoku - Bialystok
- Uniwersyteckie Centrum Kliniczne - Gdansk
- Instytut Hematologii i Transfuzjologii - Warsaw
- Hospital Vall d'Hebron - Barcelona
- Hospital Universitario La Paz - Madrid
- Hospital Regional Universitario de Málaga - Málaga
- Hospital Clinico Universitario de Salamanca - Salamanca
- West Midlands Adult Comprehensive Care Haemophilia - Birmingham
- Royal Free Hospital - Haemophilia - London
Indiana
- Indiana Hemophilia-Thromb Ctr - Indianapolis
Iowa
- University of Iowa_Iowa City - Iowa City
Pennsylvania
- Penn State MS Hershey Med Ctr - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2026-12-21 |
| Phase | Phase 1 |
What NCT07220564 shows while recruiting
NCT07220564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 223-participant average among 8 other Haemophilia A trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Haemophilia A appearing as the primary indexed condition, and to 1 intervention - of which NNC0442-0344 A is the first listed.
NCT07220564 lists 18 locations in 4 states (Other, Indiana, Iowa).
Frequently Asked Questions
What is clinical trial NCT07220564 about?
NCT07220564 is a clinical study titled "A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A". This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will ...
What is the current status of trial NCT07220564?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-10-23. Estimated completion is 2026-12-21.
What conditions does trial NCT07220564 study?
This clinical trial studies the following conditions: Haemophilia A.
What interventions are being tested in trial NCT07220564?
The interventions under investigation include: NNC0442-0344 A (DRUG).
Who is sponsoring clinical trial NCT07220564?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220564 being conducted?
This trial has 18 study locations across Indiana, Iowa, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Haemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220564's enrollment target sits among peer trials
20 9th of 8 the lowest of 8 other Haemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Haemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
RECRUITING · Phase 1
-
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
COMPLETED · Phase 1
-
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
RECRUITING
-
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI